| Summary: | 碩士 === 朝陽科技大學 === 財務金融系 === 104 === In recent years, with the efforts of Taiwan’s government and researcher, the scale of Biotech Industry in Taiwan has grown significantly. A Taiwan Bio-economic program has been started in 1 JAN 2016. It hopes to train research and development talents and sales personnel, and also to sell the products overseas.
Do the Companies have the efficiency with a good reputation as well as high profit? Do the companies exist high expenses with bad performance?
This research wants to use Data Envelopment Analysis (DEA) to analyze 95 Biotechnology Companies business performance in Taiwan. This research takes “fixed asset”, “R&D”, “sales expense” as input factor and “net income” as output factor. We use BCG Matrix to distinguish benchmark companies that can be imitated. The empirical results show that about 68.4% companies doesn’t achieve the optimum production scale in which managers should consider input reduction, and 31.6% good performance companies which represent the efficiency of distribution and resourcing. In addition, BCG Matrix’s results present that the market share and the efficient value of the benchmark companies are higher than the average industry group, which may become the subject of imitating and learning. Those companies are St. Shine, China Chemical, GKB, Standard Chemical, Johnson Health Tech., Hi-Clearance, Lotus Pharm., Microlife, TTY Biopharm, Synmosa, SCI Pharmtech, Rossmax, Center Lab., Microbio, United Orthopedic, Tyson, MedFirst, TaiDoc, FRMSL, ShareHope, TCI.
|
|---|
